Palifermin
From Wikipedia, the free encyclopedia
|
Palifermin
|
|
| Systematic (IUPAC) name | |
| ? | |
| Identifiers | |
| CAS number | |
| ATC code | V03 |
| PubChem | ? |
| DrugBank | |
| Chemical data | |
| Formula | C721H1142N202O204S9 |
| Mol. mass | 16192.7 g/mol |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | ? |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | ? |
Palifermin is a human keratinocyte growth factor (KGF) produced by recombinant DNA technology and differs slightly from endogenous human KGF. It is often used as a treatment for severe oral mucositis in patients with hematologic malignancies receiving myelotoxic therapy requiring hematopoietic stem cell support.. This drug is known by the tradename "Kepivance™" and is produced by the human therapeutics company Amgen.
[edit] External links
 |
This medical treatment article is a stub. You can help Wikipedia by expanding it. |
